# Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

> **NCT03673670** · PHASE2 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 79 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** RPL554 Suspension
- **DRUG:** Placebo
- **DRUG:** Tiotropium/olodaterol (Respimat)

## Key facts

- **NCT ID:** NCT03673670
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-16
- **Primary completion:** 2018-11-13
- **Final completion:** 2018-11-13
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673670, "Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03673670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*